Q1 EPS Forecast for Dianthus Therapeutics Cut by Analyst

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Equities research analysts at HC Wainwright reduced their Q1 2026 earnings per share (EPS) estimates for Dianthus Therapeutics in a report issued on Monday, March 9th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($1.51) per share for the quarter, down from their prior forecast of ($0.92). HC Wainwright currently has a “Buy” rating and a $130.00 target price on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q2 2026 earnings at ($1.55) EPS, Q3 2026 earnings at ($1.59) EPS, Q4 2026 earnings at ($1.63) EPS, FY2026 earnings at ($6.21) EPS, FY2027 earnings at ($6.04) EPS, FY2028 earnings at ($6.58) EPS, FY2029 earnings at ($0.58) EPS and FY2030 earnings at $8.98 EPS.

Several other research firms also recently issued reports on DNTH. Wedbush increased their price objective on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the company an “outperform” rating in a report on Tuesday. Jefferies Financial Group set a $98.00 target price on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a research note on Monday. Robert W. Baird upped their price target on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday. Oppenheimer raised their price target on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research note on Monday. Finally, TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $115.33.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $85.84 on Thursday. The firm has a fifty day moving average of $50.98 and a 200 day moving average of $41.92. The firm has a market cap of $3.71 billion, a PE ratio of -20.94 and a beta of 1.56. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $88.02.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The business had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.40 million.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new stake in shares of Dianthus Therapeutics during the second quarter worth $27,000. Parkside Financial Bank & Trust lifted its stake in shares of Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after buying an additional 540 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Dianthus Therapeutics in the fourth quarter worth about $40,000. Russell Investments Group Ltd. acquired a new position in Dianthus Therapeutics during the third quarter worth about $64,000. Finally, Tower Research Capital LLC TRC boosted its position in Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after acquiring an additional 3,317 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Trending Headlines about Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “go” decision for the CAPTIVATE CIDP trial based on an interim responder analysis — management signaled an early advancement decision that sets a major clinical catalyst (topline CIDP data expected later). This materially boosts the company’s clinical outlook and is a primary driver of recent upside. Go Decision Article
• Positive Sentiment: Multiple analyst upgrades and price‑target increases (examples: Truist to $110, Raymond James to $123, Robert W. Baird to $132, HC Wainwright bullish, Guggenheim reiterates buy) are increasing buy‑side conviction and likely supporting higher stock bids. Truist Price Target HC Wainwright Note
• Neutral Sentiment: Dianthus priced an upsized underwritten offering to raise roughly $625M (7,313,582 shares at $81.00 plus pre‑funded warrants), providing substantial cash to fund development programs — this reduces financing risk but increases share count and potential supply. Closing subject to customary conditions; underwriters have a 30‑day option for more shares. Offering Press Release
• Negative Sentiment: News of the stock offering and earlier coverage of a proposed $400M deal prompted near‑term selling and headlines about share weakness — issuance at the market can create downward pressure despite favorable pricing, which likely explains intraday pullbacks after the clinical headlines. Offering Reaction
• Negative Sentiment: Company disclosed a new AI integration–related risk (cyber, privacy, reputational exposure). This is an incremental risk factor that could concern some institutional investors focused on governance and operational risk. AI Risk Disclosure

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.